Full Breakdown
Emcure Pharmaceuticals Reduces Price of Poviztra to Enhance Accessibility
4/3/2026, 10:44:40 AM
Price Reduction Announcement
Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug Poviztra® (semaglutide injection), effective April 3, 2026. The price will decrease by up to 55%, with the starting price set at INR3,999 per month for the lowest dosage (0.25 mg), down from INR8,790. This adjustment aims to make the drug more accessible to a broader patient base in India, particularly as obesity and related health issues become increasingly prevalent.
Context of the Price Cut
Poviztra is a semaglutide injection, a molecule that has been on the market for nearly a decade and is recognized for its efficacy in managing obesity. Emcure is the first Indian company to exclusively distribute and commercialize Poviztra, which is a second brand of Novo Nordisk’s semaglutide injection for obesity. The drug is available in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The price revision is part of Emcure's strategy to address the obesity epidemic in India, where approximately 254 million individuals are affected by generalized obesity.
Competitive Landscape
The price cuts by Emcure come in the wake of similar reductions announced by Novo Nordisk for its diabetes and weight loss drugs, Ozempic and Wegovy. Novo Nordisk has reduced the price of Ozempic by 36% and Wegovy by 48%, aligning their base dosage prices at INR5,660 per month. These moves are expected to intensify competition in India's GLP-1 therapy market, with Novo Nordisk leveraging its established reputation among healthcare professionals to maintain market share against domestic competitors like Dr. Reddy's Laboratories and Sun Pharmaceutical Industries.
Official Statements & Responses
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, stated that the price revision is a crucial step towards addressing the obesity epidemic in India. He emphasized that the reduced pricing will support Emcure's commitment to improving health outcomes and increasing access to scientifically validated weight-management therapies.
Criticism & Opposition
While the price reductions are generally seen as a positive step towards improving access to obesity treatments, some industry experts express concerns about the long-term sustainability of such aggressive pricing strategies. They argue that while initial access may improve, it could lead to challenges in maintaining product quality and availability in the future.
Verbatim Quotes
- “The reduced pricing will support Emcure's ongoing commitment to improving health outcomes and increasing access to scientifically validated weight-management therapies,” — Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals.
- “We realised three-four months back that we need to change the access point,” — Vikrant Shrotriya, Head of Novo Nordisk India.
What's Next
As the price reductions take effect, both Emcure and Novo Nordisk will likely monitor market responses closely. The ongoing competition may lead to further adjustments in pricing strategies and product offerings, reflecting the evolving landscape of obesity management in India.
